A recent study from Stem Cell Program, Boston Children’s Hospital, Boston, MA, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA; and Harvard Stem Cell Institute, Cambridge, MA, USA shows that “The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation.” This study was published in the July 31 2014 Cancer Cell (The number 1 journal in basic Cancer biology) by Prof Fernando D. Camargo, Annie M. Tremblay, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based Differentiation Therapy for Embryonal Rhabdomyosarcoma: MiRNA-506 inhibits the activation of satellite cells and the development of Rhabdomyosarcoma via down regulation of its target gene. This study suggests that miR-506, by increasing the expression of MYOD1 and MEF2, it may promote Embryonal Rhabdomyosarcoma differentiation. Together, this study suggests that pharmacological formulations encompassing“miR-506 activators” may be used to treat Embryonal Rhabdomyosarcoma.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based Differentiation Therapy for Embryonal Rhabdomyosarcoma: MiRNA-506 inhibits the activation of satellite cells and the development of Rhabdomyosarcoma via down regulation of its target gene, 6/August/2014, 8.19 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation